LARIAM
LOE ApproachingNDAORALTABLET
Approved
May 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LARIAM (mefloquine) is an oral antimalarial small-molecule tablet approved by the FDA in 1989 for malaria prevention and treatment. The drug is indicated for patients traveling to or living in malaria-endemic regions. It works as a blood schizonticide, targeting the erythrocytic stage of Plasmodium parasites.
LOE Approaching
Product lifecycle is in LOE-approaching phase with moderate competitive pressure (30), suggesting the brand team is focused on lifecycle extension and managing market transition rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LARIAM offers limited career growth potential given its LOE-approaching lifecycle stage and lack of linked job openings, making it a mature portfolio product rather than a career acceleration opportunity. Roles on this product typically focus on line maintenance, market access, and managed transition to generic erosion rather than innovation or market expansion.
Brand Manager
Worked on LARIAM at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.